TY - JOUR
T1 - Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial
AU - Requena-Ibáñez, Juan Antonio
AU - Santos-Gallego, Carlos García
AU - Rodriguez-Cordero, Anderly
AU - Vargas-Delgado, Ariana Patricia
AU - Badimón, Juan José
N1 - Publisher Copyright:
© 2022 Diabetes India
PY - 2022/2
Y1 - 2022/2
N2 - Background and aims: Initially considered as just anti-diabetic agents, SGLT2-i show remarkable cardiac and renal benefits independently of its hypoglycemic activity. Methods: We used the Kansas City Cardiomyopathy Questionnaire (KCCQ), which has recently been qualified as a Clinical Outcome Assessment, in the EMPATROPISM trial. Results: A significant mean improvement of 22 points with KCCQ was seen with Empagliflozin versus only 2 points in the Placebo. The proportion of patients experiencing clinically important changes in the Empagliflozin group was higher. Patients with the lowest starting KCCQ score saw significantly greater improvements. Conclusions: Empagliflozin benefits quality of life in the non-diabetic, ethnic minority represented, EMPATROPISM trial population.
AB - Background and aims: Initially considered as just anti-diabetic agents, SGLT2-i show remarkable cardiac and renal benefits independently of its hypoglycemic activity. Methods: We used the Kansas City Cardiomyopathy Questionnaire (KCCQ), which has recently been qualified as a Clinical Outcome Assessment, in the EMPATROPISM trial. Results: A significant mean improvement of 22 points with KCCQ was seen with Empagliflozin versus only 2 points in the Placebo. The proportion of patients experiencing clinically important changes in the Empagliflozin group was higher. Patients with the lowest starting KCCQ score saw significantly greater improvements. Conclusions: Empagliflozin benefits quality of life in the non-diabetic, ethnic minority represented, EMPATROPISM trial population.
KW - Anti-diabetic agents
KW - EMPATROPISM
KW - Empagliflozin
KW - Heart failure
KW - SGLT2-Inhibitors
UR - https://www.scopus.com/pages/publications/85123871849
U2 - 10.1016/j.dsx.2022.102417
DO - 10.1016/j.dsx.2022.102417
M3 - Article
C2 - 35121204
AN - SCOPUS:85123871849
SN - 1871-4021
VL - 16
JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews
JF - Diabetes and Metabolic Syndrome: Clinical Research and Reviews
IS - 2
M1 - 102417
ER -